DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP 3.2 MG
DOPAMINE HYDROCHLORIDE : 3.2 MG DEXTROSE : 50 MG · DIN 00761834 · BAXTER CORPORATION
Health Canada status: MARKETED
What is DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP?
DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP 3.2 MG contains DOPAMINE HYDROCHLORIDE : 3.2 MG DEXTROSE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00761834, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Dec-1990. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP used for?
Correction of hemodynamic imbalances in shock syndrome due to MI, trauma, endotoxic septicemia, open heart surgery, renal failure, and chronic cardiac decompensation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00761834 |
|---|---|
| Brand name | DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP |
| Generic / active ingredient | DOPAMINE HYDROCHLORIDE : 3.2 MG DEXTROSE : 50 MG |
| Manufacturer | BAXTER CORPORATION |
| Strength | 3.2 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C01CA04 DOPAMINE |
| AHFS class | 12:12.08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1990 |
| Original market date | 1990-12-31 00:00:00 |
How is it administered?
Individual titration. Start at 2-5 mcg/kg/min, increasing to 20-50 mcg/kg/min in seriously ill patients. Administer via large vein to avoid extravasation. Do not bolus.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-25°C; brief exposure up to 40°C permitted. Avoid excessive heat. Protect from light and freezing.
How is it supplied?
VIAFLEX plastic containers in 250 mL and 500 mL volumes.
Contraindications
Pheochromocytoma; uncorrected tachyarrhythmias or ventricular fibrillation. Known allergy to corn or corn products (due to dextrose).
Warnings and precautions
Risk of tissue necrosis/sloughing with extravasation (antidote: phentolamine). Monitor for peripheral ischemia, gangrene, and sulfite sensitivity (contains sodium bisulfite). Avoid hypovolemia.
What can be used instead?
Other Canadian products sharing ATC code C01CA04 DOPAMINE. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP | 50 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761850 |
| DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP | 1.6 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761826 |
| DOPAMINE HCL INJ 4% | 40 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00423823 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00619701 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00619698 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00782394 |
| INTROPIN INJECTION 40MG/ML | 40 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01914014 |
Who else supplies DOPAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOPAMINE appears in 16 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.